Here's Why Dermira Stock Is Soaring Today
Shares of Dermira (NASDAQ: DERM), a dermatology-focused biopharmaceutical company, shot up in response to a potential competitor's clinical trial failure. The demise of AnaptysBio's (NASDAQ: ANAB) experimental eczema treatment has lifted Dermira's stock price 22.1% higher as of 1:55 p.m. on Friday.
Dermira's first drug, Qbrexza, a treatment for excessive underarm sweating, doesn't look as if it will generate enough sales to cover the company's operating expenses. That puts a lot of pressure on an eczema candidate called lebrikizumab that Dermira licensed from Roche (OTC: RHHBY) a couple of years ago.
Image source: Getty Images.
Source Fool.com
